0001629137 false 0001629137 2020-03-03 2020-03-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________

 

Form 8-K
_____________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 3, 2020

 

Global Blood Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

 

Delaware 001-37539 27-4825712
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

 

171 Oyster Point Blvd., Suite 300

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

 

(650) 741-7700

(Registrant's telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share GBT The NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

Our Chief Medical Officer, Joshua Lehrer-Graiwer, M.D., has resigned from Global Blood Therapeutics, Inc., effective April 17, 2020, to pursue an opportunity outside the company. Dr. Lehrer’s decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices.

 

 

 

 

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Global Blood Therapeutics, Inc.
     
     
Date: March 3, 2020 By:  /s/ Jeffrey Farrow  
    Jeffrey Farrow  
    Chief Financial Officer
(Principal Financial Officer)